SlideShare a Scribd company logo
EFFECTIVE PHARMACEUTICAL LIFE
CYCLE MANAGEMENT PLANNING
Optimizing Product Value over a Drug’s Lifespan
Outline
1. Putting the Right Team in
Place
2. Timing for Maximum Impact
3. Components of an Effective
Process
4. Common Pitfalls to Avoid
5. The Value-Add of External
Partners
Putting the
Right Team
in Place
A cross-functional approach increases key stakeholder
engagement, helps uncover more innovative opportunities,
and ensures broad organizational support.
Putting the Right Team in Place
Commercial Medical
Clinical Manufacturing
Regulatory Tech-Ops
Cross-Functional
Departments to Include
in LCM Planning
Timing for
Maximum
Impact
Timing for Maximum Impact
Product life cycle management planning should start early during the pre-clinical phase to
maximize product potential by ensuring the timely development and launch of high value
indications, formulations, and other LCM strategies.
Commercialization
Patent Filing Launch
Clinical Development
Loss of
Exclusivity
Early LCM Traditional LCM
150 Years 5 10 20 25 30
CashFlow
Early vs Traditional Life Cycle Management
Components
of an
Effective
Process
Idea
Generation
Evaluation
Framework
Comprehensive Research
& Data Collection
Opportunity
Evaluation &
Prioritization
Plan Approval,
Communication &
Implementation
Components of an Effective Process
Life sciences companies
with products across
several therapeutic areas
can benefit from a
consistent life cycle
management approach
by making effective
opportunity comparisons
across the organizational
portfolio and guiding
resource allocation
accordingly.
Common
Pitfalls to
Avoid
Common Pitfalls to Avoid
Product life cycle management mistakes fall into one of three categories:
Process Organizational Resource
• Waiting too late to initiate the life cycle planning process
• Lack of an objective process to identify, evaluate, and prioritize options
• Limited regional input in generating concepts
• Insufficient funding to support key recommendations
• Not enlisting the support of an experienced partner
• LCM not embraced as an organizational priority
• Failing to ensure consistent execution and governance
• Not having the appropriate functional areas engaged
Process
Organizational
Resource
Common Pitfalls to Avoid
The Value-Add
of External
Partners
The Value-Add of External Partners
Working with an
outside partner helps
enable pharma
companies to develop
the most effective
product life cycle
management plans.
Here are 5 reasons to
team up with an
experienced partner:
Knowledge of Industry Best Practices & Innovative Solutions
Proprietary Frameworks and Models
Consistent Life Cycle Management Process
Ensuring Cross-Functional Engagement
Integrated Solutions Spanning All Life Cycle Stages
Philip Vorhies is a Strategy Partner at RxC
International with over 20 years of
biopharmaceutical experience. Philip has
deep expertise in new product strategy and
commercial excellence. He has successfully
assisted numerous clients in the areas of
product launch strategy, brand and
portfolio strategy, and life cycle planning.
Nick DeSanctis is an Executive Partner at RxC
International with over 25 years of
leadership in the pharmaceutical
industry. Nick is an expert in new product
planning and driving portfolio value
through portfolio management, life cycle
management, target value profile
development, and therapeutic area strategy.
About the Authors
About RxC International
We are a premier life sciences management consulting firm with deep
expertise in Corporate Strategy, New Product Strategy, and
Commercialization. Learn more about us by clicking an image below:
Corporate Strategy New Product Strategy Commercialization
Want More?
Visit our Life Cycle Management Resource Center to
access our library of articles, case studies, and other
LCM resources.
Visit Our Resource Center

More Related Content

What's hot

Pharma marketing
Pharma marketingPharma marketing
Pharma marketing
Uzair Ahmed
 
Pharma Pricing & Market Access
Pharma Pricing & Market AccessPharma Pricing & Market Access
Pharma Pricing & Market Access
3GDR
 
10 ten best, average and worst Points of Pharmaceutical marketing
10 ten best, average and worst Points of Pharmaceutical marketing10 ten best, average and worst Points of Pharmaceutical marketing
10 ten best, average and worst Points of Pharmaceutical marketing
Anjum Iqbal
 
Drug value optimization excerpts
Drug value optimization   excerptsDrug value optimization   excerpts
Drug value optimization excerpts
Jean-Michel Peny
 
Market Access
Market AccessMarket Access
Market Access
Gergana Nash
 
The future of pharma marketing
The future of pharma marketingThe future of pharma marketing
The future of pharma marketing
Farhad Zargari
 
Ppt of pharmaceutical economy
Ppt of pharmaceutical economyPpt of pharmaceutical economy
Ppt of pharmaceutical economy
Muhammed hamed albuissa
 
Pharmaceutical Supply Chain
Pharmaceutical Supply ChainPharmaceutical Supply Chain
Pharmaceutical Supply Chain
Divya Kumar
 
CLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOLCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL
Jayvantika Raulji
 
Pharmaceutical Marketing
Pharmaceutical MarketingPharmaceutical Marketing
Pharmaceutical Marketing
Ravindran Kanningat
 
Pharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the OpportunitiesPharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the Opportunities
European Industrial Pharmacists Group
 
New drug application
New drug applicationNew drug application
New drug application
Bindu Kshtriya
 
Rational use of drugs -1
Rational use of drugs -1Rational use of drugs -1
Rational use of drugs -1
Muhammad Saalim
 
Strategy to incorporate pharmacoeconomics into pharmacotherapy
Strategy to incorporate pharmacoeconomics into pharmacotherapy Strategy to incorporate pharmacoeconomics into pharmacotherapy
Strategy to incorporate pharmacoeconomics into pharmacotherapy
Ravi Kumar Yadav
 
Supply chain in pharma sector
Supply chain in pharma sectorSupply chain in pharma sector
Supply chain in pharma sector
Piyush Virmani
 
Biowaivers
Biowaivers Biowaivers
Professional practice-standards-v4
Professional practice-standards-v4Professional practice-standards-v4
Professional practice-standards-v4
Boris cvijic
 
Market survey on azithromycin and amoxicillin with clavulanic acid
Market survey on azithromycin and amoxicillin with clavulanic acidMarket survey on azithromycin and amoxicillin with clavulanic acid
Market survey on azithromycin and amoxicillin with clavulanic acid
Mitesh Shah
 
Quantification of medicines need
Quantification of medicines needQuantification of medicines need
Quantification of medicines need
Mmedsc Hahm
 
Drug utilization review 1
Drug utilization review 1Drug utilization review 1
Drug utilization review 1
Kainat Fatima
 

What's hot (20)

Pharma marketing
Pharma marketingPharma marketing
Pharma marketing
 
Pharma Pricing & Market Access
Pharma Pricing & Market AccessPharma Pricing & Market Access
Pharma Pricing & Market Access
 
10 ten best, average and worst Points of Pharmaceutical marketing
10 ten best, average and worst Points of Pharmaceutical marketing10 ten best, average and worst Points of Pharmaceutical marketing
10 ten best, average and worst Points of Pharmaceutical marketing
 
Drug value optimization excerpts
Drug value optimization   excerptsDrug value optimization   excerpts
Drug value optimization excerpts
 
Market Access
Market AccessMarket Access
Market Access
 
The future of pharma marketing
The future of pharma marketingThe future of pharma marketing
The future of pharma marketing
 
Ppt of pharmaceutical economy
Ppt of pharmaceutical economyPpt of pharmaceutical economy
Ppt of pharmaceutical economy
 
Pharmaceutical Supply Chain
Pharmaceutical Supply ChainPharmaceutical Supply Chain
Pharmaceutical Supply Chain
 
CLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOLCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL
 
Pharmaceutical Marketing
Pharmaceutical MarketingPharmaceutical Marketing
Pharmaceutical Marketing
 
Pharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the OpportunitiesPharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the Opportunities
 
New drug application
New drug applicationNew drug application
New drug application
 
Rational use of drugs -1
Rational use of drugs -1Rational use of drugs -1
Rational use of drugs -1
 
Strategy to incorporate pharmacoeconomics into pharmacotherapy
Strategy to incorporate pharmacoeconomics into pharmacotherapy Strategy to incorporate pharmacoeconomics into pharmacotherapy
Strategy to incorporate pharmacoeconomics into pharmacotherapy
 
Supply chain in pharma sector
Supply chain in pharma sectorSupply chain in pharma sector
Supply chain in pharma sector
 
Biowaivers
Biowaivers Biowaivers
Biowaivers
 
Professional practice-standards-v4
Professional practice-standards-v4Professional practice-standards-v4
Professional practice-standards-v4
 
Market survey on azithromycin and amoxicillin with clavulanic acid
Market survey on azithromycin and amoxicillin with clavulanic acidMarket survey on azithromycin and amoxicillin with clavulanic acid
Market survey on azithromycin and amoxicillin with clavulanic acid
 
Quantification of medicines need
Quantification of medicines needQuantification of medicines need
Quantification of medicines need
 
Drug utilization review 1
Drug utilization review 1Drug utilization review 1
Drug utilization review 1
 

Similar to Effective Pharmaceutical Life Cycle Management Planning: Optimizing Product Value over a Drug's Lifespan

ProcureConHealthcare 2015
ProcureConHealthcare 2015ProcureConHealthcare 2015
ProcureConHealthcare 2015
Cristian Lienas
 
10151-ProcureConHealthcare-FINAL
10151-ProcureConHealthcare-FINAL10151-ProcureConHealthcare-FINAL
10151-ProcureConHealthcare-FINAL
Alejandro Basso
 
TransCelerate Overview - Quality Management System Initiave
TransCelerate Overview - Quality Management System Initiave TransCelerate Overview - Quality Management System Initiave
TransCelerate Overview - Quality Management System Initiave
TransCelerate
 
PAREXEL BioPharm Unit
PAREXEL BioPharm UnitPAREXEL BioPharm Unit
PAREXEL BioPharm Unit
Neil Butera
 
3716_A5_Capabilities_Brochure_R7
3716_A5_Capabilities_Brochure_R73716_A5_Capabilities_Brochure_R7
3716_A5_Capabilities_Brochure_R7
Catharine S
 
pc15147_brochure
pc15147_brochurepc15147_brochure
pc15147_brochure
Daria Binder
 
Murray CV 2016
Murray CV 2016Murray CV 2016
Murray CV 2016
Stuart Murray
 
Clinical Compliance Solutions Summary
Clinical Compliance Solutions SummaryClinical Compliance Solutions Summary
Clinical Compliance Solutions Summary
Sharon Reinhard, M.S.
 
1. Introduction to regulatory affairs (2).pptx
1. Introduction to regulatory affairs (2).pptx1. Introduction to regulatory affairs (2).pptx
1. Introduction to regulatory affairs (2).pptx
MdJubair13
 
Pharmaceutical preformulation and formulation
Pharmaceutical preformulation  and formulationPharmaceutical preformulation  and formulation
Pharmaceutical preformulation and formulation
Suchandra03
 
Aai Pharma Sr Director Formulations
Aai Pharma Sr Director FormulationsAai Pharma Sr Director Formulations
Aai Pharma Sr Director Formulations
pmaffuid
 
Stabicon Corporate Presentation
Stabicon Corporate PresentationStabicon Corporate Presentation
Stabicon Corporate Presentation
STABICON LIFE SCIENCE
 
TransCelerate Overview - Patient Experience Initiative
TransCelerate Overview - Patient Experience Initiative TransCelerate Overview - Patient Experience Initiative
TransCelerate Overview - Patient Experience Initiative
TransCelerate
 
Regulatory Affairs
Regulatory AffairsRegulatory Affairs
Regulatory Affairs
ShabeenaZaidi
 
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Yavuz Silay
 
Success Factors and Failure Points in Cardiovascular Product Launches Report ...
Success Factors and Failure Points in Cardiovascular Product Launches Report ...Success Factors and Failure Points in Cardiovascular Product Launches Report ...
Success Factors and Failure Points in Cardiovascular Product Launches Report ...
Best Practices
 
Amatsigroup CORP PRES HUMAN HEALTH 19 05 2016
Amatsigroup CORP PRES HUMAN HEALTH 19 05 2016Amatsigroup CORP PRES HUMAN HEALTH 19 05 2016
Amatsigroup CORP PRES HUMAN HEALTH 19 05 2016
Marie-Christine Bodinier
 
INC Research Consulting v1
INC Research Consulting v1INC Research Consulting v1
INC Research Consulting v1
Douglas Niven, PhD
 
Success Factors and Failure Points in Metabolic Product Launches Report Summary
Success Factors and Failure Points in Metabolic Product Launches Report SummarySuccess Factors and Failure Points in Metabolic Product Launches Report Summary
Success Factors and Failure Points in Metabolic Product Launches Report Summary
Best Practices
 
Pfizer strategy for internationalization
Pfizer strategy for internationalizationPfizer strategy for internationalization
Pfizer strategy for internationalization
Aamir chouhan
 

Similar to Effective Pharmaceutical Life Cycle Management Planning: Optimizing Product Value over a Drug's Lifespan (20)

ProcureConHealthcare 2015
ProcureConHealthcare 2015ProcureConHealthcare 2015
ProcureConHealthcare 2015
 
10151-ProcureConHealthcare-FINAL
10151-ProcureConHealthcare-FINAL10151-ProcureConHealthcare-FINAL
10151-ProcureConHealthcare-FINAL
 
TransCelerate Overview - Quality Management System Initiave
TransCelerate Overview - Quality Management System Initiave TransCelerate Overview - Quality Management System Initiave
TransCelerate Overview - Quality Management System Initiave
 
PAREXEL BioPharm Unit
PAREXEL BioPharm UnitPAREXEL BioPharm Unit
PAREXEL BioPharm Unit
 
3716_A5_Capabilities_Brochure_R7
3716_A5_Capabilities_Brochure_R73716_A5_Capabilities_Brochure_R7
3716_A5_Capabilities_Brochure_R7
 
pc15147_brochure
pc15147_brochurepc15147_brochure
pc15147_brochure
 
Murray CV 2016
Murray CV 2016Murray CV 2016
Murray CV 2016
 
Clinical Compliance Solutions Summary
Clinical Compliance Solutions SummaryClinical Compliance Solutions Summary
Clinical Compliance Solutions Summary
 
1. Introduction to regulatory affairs (2).pptx
1. Introduction to regulatory affairs (2).pptx1. Introduction to regulatory affairs (2).pptx
1. Introduction to regulatory affairs (2).pptx
 
Pharmaceutical preformulation and formulation
Pharmaceutical preformulation  and formulationPharmaceutical preformulation  and formulation
Pharmaceutical preformulation and formulation
 
Aai Pharma Sr Director Formulations
Aai Pharma Sr Director FormulationsAai Pharma Sr Director Formulations
Aai Pharma Sr Director Formulations
 
Stabicon Corporate Presentation
Stabicon Corporate PresentationStabicon Corporate Presentation
Stabicon Corporate Presentation
 
TransCelerate Overview - Patient Experience Initiative
TransCelerate Overview - Patient Experience Initiative TransCelerate Overview - Patient Experience Initiative
TransCelerate Overview - Patient Experience Initiative
 
Regulatory Affairs
Regulatory AffairsRegulatory Affairs
Regulatory Affairs
 
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
 
Success Factors and Failure Points in Cardiovascular Product Launches Report ...
Success Factors and Failure Points in Cardiovascular Product Launches Report ...Success Factors and Failure Points in Cardiovascular Product Launches Report ...
Success Factors and Failure Points in Cardiovascular Product Launches Report ...
 
Amatsigroup CORP PRES HUMAN HEALTH 19 05 2016
Amatsigroup CORP PRES HUMAN HEALTH 19 05 2016Amatsigroup CORP PRES HUMAN HEALTH 19 05 2016
Amatsigroup CORP PRES HUMAN HEALTH 19 05 2016
 
INC Research Consulting v1
INC Research Consulting v1INC Research Consulting v1
INC Research Consulting v1
 
Success Factors and Failure Points in Metabolic Product Launches Report Summary
Success Factors and Failure Points in Metabolic Product Launches Report SummarySuccess Factors and Failure Points in Metabolic Product Launches Report Summary
Success Factors and Failure Points in Metabolic Product Launches Report Summary
 
Pfizer strategy for internationalization
Pfizer strategy for internationalizationPfizer strategy for internationalization
Pfizer strategy for internationalization
 

Recently uploaded

pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Kanhu Charan
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
MedicoseAcademics
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Kosmoderma Academy Of Aesthetic Medicine
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
Dr. Ahana Haroon
 

Recently uploaded (20)

pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan PatroJune 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of RespirationThe Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USENARCOTICS- POLICY AND PROCEDURES FOR ITS USE
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
 

Effective Pharmaceutical Life Cycle Management Planning: Optimizing Product Value over a Drug's Lifespan

  • 1. EFFECTIVE PHARMACEUTICAL LIFE CYCLE MANAGEMENT PLANNING Optimizing Product Value over a Drug’s Lifespan
  • 2. Outline 1. Putting the Right Team in Place 2. Timing for Maximum Impact 3. Components of an Effective Process 4. Common Pitfalls to Avoid 5. The Value-Add of External Partners
  • 4. A cross-functional approach increases key stakeholder engagement, helps uncover more innovative opportunities, and ensures broad organizational support. Putting the Right Team in Place Commercial Medical Clinical Manufacturing Regulatory Tech-Ops Cross-Functional Departments to Include in LCM Planning
  • 6. Timing for Maximum Impact Product life cycle management planning should start early during the pre-clinical phase to maximize product potential by ensuring the timely development and launch of high value indications, formulations, and other LCM strategies. Commercialization Patent Filing Launch Clinical Development Loss of Exclusivity Early LCM Traditional LCM 150 Years 5 10 20 25 30 CashFlow Early vs Traditional Life Cycle Management
  • 8. Idea Generation Evaluation Framework Comprehensive Research & Data Collection Opportunity Evaluation & Prioritization Plan Approval, Communication & Implementation Components of an Effective Process Life sciences companies with products across several therapeutic areas can benefit from a consistent life cycle management approach by making effective opportunity comparisons across the organizational portfolio and guiding resource allocation accordingly.
  • 10. Common Pitfalls to Avoid Product life cycle management mistakes fall into one of three categories: Process Organizational Resource
  • 11. • Waiting too late to initiate the life cycle planning process • Lack of an objective process to identify, evaluate, and prioritize options • Limited regional input in generating concepts • Insufficient funding to support key recommendations • Not enlisting the support of an experienced partner • LCM not embraced as an organizational priority • Failing to ensure consistent execution and governance • Not having the appropriate functional areas engaged Process Organizational Resource Common Pitfalls to Avoid
  • 13. The Value-Add of External Partners Working with an outside partner helps enable pharma companies to develop the most effective product life cycle management plans. Here are 5 reasons to team up with an experienced partner: Knowledge of Industry Best Practices & Innovative Solutions Proprietary Frameworks and Models Consistent Life Cycle Management Process Ensuring Cross-Functional Engagement Integrated Solutions Spanning All Life Cycle Stages
  • 14. Philip Vorhies is a Strategy Partner at RxC International with over 20 years of biopharmaceutical experience. Philip has deep expertise in new product strategy and commercial excellence. He has successfully assisted numerous clients in the areas of product launch strategy, brand and portfolio strategy, and life cycle planning. Nick DeSanctis is an Executive Partner at RxC International with over 25 years of leadership in the pharmaceutical industry. Nick is an expert in new product planning and driving portfolio value through portfolio management, life cycle management, target value profile development, and therapeutic area strategy. About the Authors
  • 15. About RxC International We are a premier life sciences management consulting firm with deep expertise in Corporate Strategy, New Product Strategy, and Commercialization. Learn more about us by clicking an image below: Corporate Strategy New Product Strategy Commercialization
  • 16. Want More? Visit our Life Cycle Management Resource Center to access our library of articles, case studies, and other LCM resources. Visit Our Resource Center